Printer Friendly

Meet the ADVIA portfolio. (Product Focus).

The ADVIA 120 Hematology System provides a CBC, six-part differential and fully automated reticulocyte analysis, designed to streamline laboratory workflow and achieve long-term economic benefits. The fixed throughput of CBC/Diff at 120 samples per hour, even on leukopenic samples, provides fast results reporting to enhance service to clinicians. Peroxidase staining makes the difference in V/BC identification, facilitating detection of abnormalities and differentiation of leukemias. Achieve sensitive detection of red cell abnormalities without expensive and time-consuming manual tests, and differentiate microcytic anemias (thalassemia, iron deficiency) and macrocytic anemias (hereditary spherocytosis, sickle cell) with the RBC and reticulocyte technology. Expanded linearity ranges enable maximimum effectiveness of costly platelet transfusions with accurate results, even at very low platelet levels. To complement the ADVIA 120, this hematology product portfolio includes the ADVIA 70, ADVIA S60 and ADVIA 60 to meet specific laboratory needs.

Carren Bersch is managing editor of MLO. J.D. Myers. BS, CT(ASCP), MAs, a laboratory scientist and sales professional in Clearwater, FL, assisted in preparing this article.
COPYRIGHT 2003 Nelson Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:blood analyzer product line
Author:Bersch, Carren
Publication:Medical Laboratory Observer
Article Type:Brief Article
Geographic Code:1USA
Date:Feb 1, 2003
Words:169
Previous Article:Cost efficiency with flexibility. (Product Focus).
Next Article:Triple treat. (Product Focus).
Topics:


Related Articles
Make your best offer.
What's new in POCT.
POC testing. (Product Focus).
Compact automated CRP analyzer. (Product Focus).
HYCOR REPORTS INCREASE IN 4TH QTR AND YEAR-END PROFIT.
HYCOR REPORTS FIRST QTR NET INCOME OF $331.000.
New-gen hematology analyzers.
DAXOR OPERATING REVENUES INCREASED BY 13% FOR 9 MONTHS.
Abaxis licenses of lyophilization technology to bioMerieux.
Point-of-care testing.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters